SBIR/STTR Research Award

Isolation of Focal Adhesion Kinase-specific Modulators

Award identifier 0849f3d30db3f769702aed8b5fe3eb226f4012924e97a0ea0a27349d6e3ba553Awarding agency Department of Defense · Army

Award amount

$730,027

Program and phase

SBIR · Phase II

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Defense
Branch
Army
Recipient company
LUNA INNOVATIONS INCORPORATED
Proposal award date
2006-01-19
Contract end date
2008-02-18
UEI
SJHFCDGKJJC5
Solicitation number
2003.2
Topic code
A03-172

Research abstract

There exists a need to develop therapeutic strategies for the pharmacological modulation of angiogenesis to maintain force readiness. Angiogenesis is the development and growth of new capillary blood vessels from the existing vasculature. While increased vascularization of wounded tissue is essential for wound healing, increased angiogenesis is also critical in the progression of several pathologies including arthritis, diabetic retinopathy, and tumor proliferation. It is also an essential process underlying tumor growth and metastasis. Technologies that can modulate the process of angiogenesis are important to maintain the warfighter at full capacity. These technologies will have long reaching effects including reduced need for evacuation and convalescence leave; and reduced the cost of operations based on a decreased need for extended medical logistical support. Recent research suggests that focal adhesion kinase (FAK) activity is closely linked to angiogenesis. During the Phase I program, the Luna team discovered several natural extracts that contained specific FAK modulators. During the Phase II program, the Luna team will purify and identify the active component from each of the extracts that specifically influence FAK activity. Additionally, the efficacy of the FAK-specific modulators on cell migration and angiogenesis in cell-based assays will be determined, along with preliminary animal testing.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

994 SBIR/STTR records share this UEI (1991–2026). Reported award amounts total $336,438,763. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Defense, National Aeronautics and Space Administration, Department of Energy, Department of Health and Human Services, National Science Foundation, Environmental Protection Agency

Agency intelligence

Department of Defense

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.